Q1 2021

Filed May 11, 2021 · 10-Q · 41 days after period end · 0001564590-21-026319

Q1 2021 · 10-Q

Revenue

$2.42M

no prior Q1 2020 on file

Net Income

-$7.26M

N/M vs Q1 2020

EPS Diluted

-$1.64

N/M vs Q1 2020

Operating Income-$6,888,000N/M

Operating Cash Flow

Same quarter

Metric	Q1 2021	Q1 2020	Q1 2019	Q1 2018
Revenue	$2.42M	—	$7.02M	$4.07M
Net Income	-$7.26M	$2.90M	-$12.02M	-$13.85M
EPS Diluted	-$1.64	$0.89	-$7.64	-$0.63

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Aptevo Therapeutics Inc. · CIK 1671584 · Engraved from SEC EDGAR